These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33782411)

  • 1. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
    Shang M; Yang H; Yang R; Chen T; Fu Y; Li Y; Fang X; Zhang K; Zhang J; Li H; Cao X; Gu J; Xiao J; Zhang Q; Liu X; Yu Q; Wang T
    Nat Commun; 2021 Mar; 12(1):1940. PubMed ID: 33782411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    Ju HQ; Lu YX; Chen DL; Zuo ZX; Liu ZX; Wu QN; Mo HY; Wang ZX; Wang DS; Pu HY; Zeng ZL; Li B; Xie D; Huang P; Hung MC; Chiao PJ; Xu RH
    J Natl Cancer Inst; 2019 Jun; 111(6):584-596. PubMed ID: 30534944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes.
    Yu C; Yang L; Cai M; Zhou F; Xiao S; Li Y; Wan T; Cheng D; Wang L; Zhao C; Huang X
    J Cell Mol Med; 2020 Jan; 24(2):1568-1577. PubMed ID: 31778025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling.
    Shi Y; Xu Y; Yao J; Yan C; Su H; Zhang X; Chen E; Ying K
    J Cell Mol Med; 2021 Jul; 25(14):7013-7027. PubMed ID: 34121323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer.
    Liu X; Liu S; Piao C; Zhang Z; Zhang X; Jiang Y; Kong C
    Cancer Sci; 2021 Dec; 112(12):4909-4919. PubMed ID: 34632667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
    Lin H; Huang B; Wang H; Liu X; Hong Y; Qiu S; Zheng J
    Cell Physiol Biochem; 2018; 51(2):991-1000. PubMed ID: 30466107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-33a-5p suppresses colorectal cancer cell growth by inhibiting MTHFD2.
    Yan Y; Zhang D; Lei T; Zhao C; Han J; Cui J; Wang Y
    Clin Exp Pharmacol Physiol; 2019 Oct; 46(10):928-936. PubMed ID: 31209892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage.
    Li G; Wu J; Li L; Jiang P
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATF4/MYC Regulates MTHFD2 to Promote NSCLC Progression by Mediating Redox Homeostasis.
    Gao Y; Feng L; Zhang L; Geng J; Zhang E
    Dis Markers; 2022; 2022():7527996. PubMed ID: 36051358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of MTHFD2 is associated with clinicopathological characteristics and poor survival in ovarian cancer, possibly by regulating MOB1A signaling.
    Cui X; Su H; Yang J; Wu X; Huo K; Jing X; Zhang S
    J Ovarian Res; 2022 Feb; 15(1):23. PubMed ID: 35135596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer.
    Lee J; Chen X; Wang Y; Nishimura T; Li M; Ishikawa S; Daikoku T; Kawai J; Tojo A; Gotoh N
    Biochem Biophys Res Commun; 2021 Dec; 584():7-14. PubMed ID: 34753066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions.
    Mo HY; Wang RB; Ma MY; Zhang Y; Li XY; Wen WR; Han Y; Tian T
    Redox Rep; 2024 Dec; 29(1):2345455. PubMed ID: 38723197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
    Nishimura T; Nakata A; Chen X; Nishi K; Meguro-Horike M; Sasaki S; Kita K; Horike SI; Saitoh K; Kato K; Igarashi K; Murayama T; Kohno S; Takahashi C; Mukaida N; Yano S; Soga T; Tojo A; Gotoh N
    Oncogene; 2019 Apr; 38(14):2464-2481. PubMed ID: 30532069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-92a Inhibits Proliferation and Induces Apoptosis by Regulating Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) Expression in Acute Myeloid Leukemia.
    Gu Y; Si J; Xiao X; Tian Y; Yang S
    Oncol Res; 2017 Aug; 25(7):1069-1079. PubMed ID: 28059050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Expression of Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) in Esophageal Squamous Cell Carcinoma and its Clinical Prognostic Significance.
    He H; Li PC; Jia W; Hu B; Ji CS
    Med Sci Monit; 2020 Feb; 26():e920259. PubMed ID: 32088725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate enzyme MTHFD2 links one-carbon metabolism to unfolded protein response in glioblastoma.
    Zhu Z; Kiang KM; Li N; Liu J; Zhang P; Jin L; He X; Zhang S; Leung GK
    Cancer Lett; 2022 Nov; 549():215903. PubMed ID: 36089117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xanthine Derivatives Reveal an Allosteric Binding Site in Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2).
    Lee LC; Peng YH; Chang HH; Hsu T; Lu CT; Huang CH; Hsueh CC; Kung FC; Kuo CC; Jiaang WT; Wu SY
    J Med Chem; 2021 Aug; 64(15):11288-11301. PubMed ID: 34337952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.
    Bonagas N; Gustafsson NMS; Henriksson M; Marttila P; Gustafsson R; Wiita E; Borhade S; Green AC; Vallin KSA; Sarno A; Svensson R; Göktürk C; Pham T; Jemth AS; Loseva O; Cookson V; Kiweler N; Sandberg L; Rasti A; Unterlass JE; Haraldsson M; Andersson Y; Scaletti ER; Bengtsson C; Paulin CBJ; Sanjiv K; Abdurakhmanov E; Pudelko L; Kunz B; Desroses M; Iliev P; Färnegårdh K; Krämer A; Garg N; Michel M; Häggblad S; Jarvius M; Kalderén C; Jensen AB; Almlöf I; Karsten S; Zhang SM; Häggblad M; Eriksson A; Liu J; Glinghammar B; Nekhotiaeva N; Klingegård F; Koolmeister T; Martens U; Llona-Minguez S; Moulson R; Nordström H; Parrow V; Dahllund L; Sjöberg B; Vargas IL; Vo DD; Wannberg J; Knapp S; Krokan HE; Arvidsson PI; Scobie M; Meiser J; Stenmark P; Berglund UW; Homan EJ; Helleday T
    Nat Cancer; 2022 Feb; 3(2):156-172. PubMed ID: 35228749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell.
    Wan X; Wang C; Huang Z; Zhou D; Xiang S; Qi Q; Chen X; Arbely E; Liu CY; Du P; Yu W
    Cell Death Dis; 2020 Aug; 11(8):649. PubMed ID: 32811824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.